The oncogenic role of IGF2BP3 was first described due to its overexpression in pancreatic cancer in 1997 5, and then IGF2BP3 modulates tumor cell fate, such as proliferation, migration, and chemo-resistance by controlling the translation and turnover of target transcripts, and regulating DNA methylation, and acetylation processes 3, 85. The gene discussed is IGF2BP3; the disease is neoplasm.